

Background

In Europe, rare diseases affect more than 30 millions persons. A rare disease is defined as being a life threatening or chronically debilitating disease which affects less than 1 person per 2000. There are between 6000 and 8000 identified rare diseases. Most of them have genetic origins (80%) and have no causal treatment.

During the last decades a big leap has been made forward with the mapping of the human genome and thus identification of many rare diseases genetic and molecular basis. This scientific progress has opened perspective for treatment discovery. Meanwhile, international and national regulations have provided legal framework for healthcare improvement in the field of rare diseases and fostered research.

But this new therapeutic era for rare diseases with an increasing number of promising proofs of concept is characterized by the young and non mature drugs development culture. It appears as an emergency to now fill the gap in translational research for rare diseases.

Pre clinical issues, early phase clinical trials' design, conception and conduction of clinical trials, patients' selection and recruitment, multinational cooperation are thus new challenges to uptake in order to accelerate and improve availability and access of therapeutic innovations.

This Eudipharm training seminar aims at raising awareness among clinical research actors on drug development specificities for rare diseases. It will contribute to provide tools and solutions for clinical research professional and project carriers thanks to the participation of clinical research experts.

Organisation Committee

Eudipharm: Behrouz Kassai, Catherine Cornu, Kent Neal

OrphanDev: Joelle Micallef, Yolande Adjibi, Marine Berro

F-CRIN: Olivier Rascol, Vincent Diebolt, Allan Wilsdorf

With the support of the **French Foundation for rare diseases**



Eudipharm

Eudipharm is a Master degree in pharmaceutical medicine offered by Université Claude Bernard in Lyon, France. In 2012, it was awarded Center of Excellence by PharmaTrain, a European consortium of Master's degrees in pharmaceutical medicine. This elective module is part of the PharmaTrain program. It aims at providing continuing professional development to those wishing to update their skills or acquire new expertise.

Place

Aix Marseille Université

Amphithéâtre Gastaud

Jardin du Pharo

57 Boulevard Charles Livon

13007 – Marseille

For more information:

Website:

www.eudipharm.net/claroline141/RARE/

www.fcrin.org/nos-actualites/actualites/accelerating-access-therapeutic-innovation

www.orphan-dev.org

Scientific Secretariat: Yolande Adjibi, Marine Berro

E-Mail: contacts@orphan-dev.org

Seminar Organisation: Atout Science Organisation

E-Mail: orphandrugseminar2013@atout-org.com

Orphan Drug & Rare disease Seminar

-Accelerating Access to Therapeutic Innovation-



-Marseille-

-17 & 18 october 2013 -

Training Seminar
organised by



Thursday October 17th 2013

08:45-9:00 - INTRODUCTION TO THE SEMINAR

Eudipharm, OrphanDev, F-CRIN

09:00-10:00 - CONFERENCES:

Rare diseases and organization for rare diseases

Prof. Nicolas Levy, Director of the French Foundation for Rare Diseases, France

Why reinforcing clinical development transnational process and organization is a necessity-Experience reporting

Prof. Evelyne Jacqz-Aigrain, National coordinator of paediatrics' investigating centers, Robert Debré Hospital, France

10:00-10:30 Coffee break

10:30-12:30 - ROUND TABLE:

Methodology of clinical trial in rare diseases

Moderator: Prof. Behrouz Kassai, Hospices Civils de Lyon, France

Design of clinical trials for small populations

Prof. Corinne Alberti, Robert Debré hospital, France

The Use of Modelling and simulating to design new trials,exmple of Dravet syndrome

Dr. Catherine Chiron & Dr. Polina Kurbatova, Necker hospital, France

Outcomes for rare diseases clinical trials

Prof. Shahram Attarian, Timone hospital, France

12:30-14:00 Lunch Break

14:00-16:00 - CONFERENCES: Improving clinical trials for rare diseases a priority for the future

Partnering in rare disease: a case study in accelerating the development for a therapy

Dr Jeremy Springhorn, Alexion Pharmaceuticals, US

Strengthening capacities for clinical trial

Prof. Joaquim Ferreira, University of Lisbon, Portugal

Patient's recruitment in clinical trials for rare diseases, a strategy to anticipate

Dr. Joelle Micallef, OrphanDev, France

Relevance of registries for clinical trials in rare diseases, how to construct them to match clinical trial needs

Prof. Paul Landais, France

16:00-16:30 Coffee break

16:30-18:00 - ROUND TABLE:

Patients' organizations and orphan drug development

Moderator: Anne Sophie Lapointe, Vaincre les Maladies Lysosomales, France

Serge Braun, French Association against Neuromuscular Diseases (AFM), France, Maria Mavris, Eurordis, Prof. Marc Nicolino, pediatric endocrinology, France, Khazal Paradis, Genzyme, Amsterdam.

20:00 Gala Diner

Friday October 18th 2013

09:00-10:00 - CONFERENCES:

From Pre-clinic to Clinic: what bridges?

Translating proof of concept in Cell model into clinical evaluation

Marc Peschanski, i-Stem, Paris, France

Translating Body of evidence into clinical evaluation

Dr Bernard Landwehrmeyer, Ulm University, Germany

10:00-10:30 Coffee Break

10:30-12:00 - CONFERENCES:

Orphan drug's development process

The Orphan Drug designation

Jordi Llinares, EMA, UK

Drugs Evaluation and development in Paediatrics,

Prof. Gerard Pons, EMA Paediatrics' Committee, France

One orphan drug development experience

Dr Luc-André Granier, Advicenne Pharma, France

12:00-13:30 Lunch Break

13:30-15:30 - ROUND TABLE:

Multinational collaboration for clinical development in rare diseases

Moderator: Prof. Jacques Demotes, ECRIN, France

How to get into a European project?

Celine Damon, Head of European Research Programs Unit Aix-Marseille University, Health NCP, H2020, France

How to initiate a European clinical trial?

Dr. Nicolas André, paediatric oncology, Timone Hospital, Marseille

The voluntary harmonization procedure

Prof. Jacques Demotes, ECRIN, France

One Start-Up experience

Eric Haloua, Promethera, Belgique

15:30 - CONCLUSION

Orphan Drug &
Rare disease
Seminar



-Accelerating Access to Therapeutic Innovation-

REGISTRATION

Register on –line: www.atout-org.com/orphandrugseminar

by E-mail to: orphandrugseminar2013@atout-org.com

by Fax : +33 4 96 15 12 51

- Please register before September 17, 2013 -

FEES BEFORE / FEES AFTER 31 JULY 2013

V.A.T. included - coffee breaks & lunches included

Academic, institution **€360/ €450**

Industry **€960 / €1200**

Student **€55 / €70**

Conférence dinner on Thursday ,17 october 2013 **€55**